Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
Pharming Group N.V. Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year e...